Lower chloride use in intravenous fluids for critically ill patients may lower risk of kidney injury

In a pilot study assessing the effect of different levels of chloride in intravenous fluids administered to critically ill patients in an intensive care unit, restricting the amount of chloride administration was associated with a significant decrease in the incidence of acute kidney injury and the use of renal replacement therapy, according to a study in the October 17 issue of JAMA.

“The administration of intravenous chloride is ubiquitous in critical care medicine,” according to background in the article. Many of the fluids used for hydration and resuscitation contain supraphysiological (an amount greater than normally found in the body) concentrations of chloride, which may have several adverse effects, including renal vasoconstriction and decreased glomerular filtration rate (GFR). “These effects of chloride on the kidney are of potential concern because acute kidney injury (AKI) is associated with high mortality and may require treatment with costly and invasive renal replacement therapy (RRT).”

Nor’azim Mohd Yunos, M.D., of Monash University Sunway Campus, Malaysia, and colleagues conducted a study to examine whether a chloride-restrictive intravenous fluid strategy for critically ill patients might be associated with a decreased incidence and severity of AKI compared with a chloride-liberal intravenous strategy. The study included 760 patients admitted to an intensive care unit (ICU) during the control period (February 18 to August 17, 2008) compared with 773 patients admitted during the intervention period (February 18 to August 17, 2009) at a university-affiliated hospital in Melbourne, Australia. During the control period, patients received standard intravenous fluids. After a 6-month phase-out period (August 18, 2008 to February 17, 2009), any use of chloride-rich intravenous fluids (0.9 percent saline, 4 percent succinylated gelatin solution, or 4 percent albumin solution) was restricted to attending specialist approval only during the intervention period; patients instead received a lactated solution (Hartmann solution), a balanced solution (Plasma-Lyte 148), and chloride-poor 20 percent albumin.

The primary outcomes included increase from baseline to peak creatinine level in the ICU and incidence of AKI according to the risk, injury, failure, loss, end-stage (RIFLE) classification. Secondary analysis outcomes included the need for renal replacement therapy, length of stay in ICU and hospital, and survival.

During the intervention period, chloride administration decreased from 694 to 496 mmol/patient. The chloride-restrictive strategy was associated with a significantly lower increase in serum creatinine level during ICU stay and a decrease in the incidence of injury and failure class of RIFLE-defined AKI. “It was further associated with a decrease in RRT use for 78 patients (10 percent) during the control period vs. 49 patients (6.3 percent) during the intervention period,” the authors write.

After adjusting for various factors, including sex, diagnosis, operative status, baseline serum creatinine level, and admission type (elective or emergency), the overall incidence of injury and failure class of RIFLE-defined AKI and the use of RRT remained significantly lower during the intervention period. In addition, there were no differences in long-term dialysis requirements, in-hospital mortality, hospital or ICU length of stay, or need for RRT after hospital discharge.

“The findings of this study show that a chloride-restrictive intravenous strategy is associated with a decrease in the incidence of the more severe stages of AKI and the use of RRT. These findings, together with the previously reported observations that a chloride-liberal intravenous strategy can be associated with higher cost, and the easy availability of cheap alternatives suggest the need to exert prudence in the administration of fluids with supraphysiological concentrations of chloride, especially in critically ill patients with evidence of early acute renal dysfunction or at risk of acute dysfunction,” the researchers write. “Our findings need to be confirmed in different health care systems and different ICUs.”

###

Editor’s Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Story reported receiving an unconditional research grant from Baxter Healthcare to fund other fluid studies. No other authors reported disclosures.

Editorial: Saving the Kidneys by Sparing Intravenous Chloride?

Sushrut S. Waikar, M.D., M.P.H., of Brigham and Women’s Hospital and Harvard Medical School, Boston, and Wolfgang C. Winkelmayer, M.D., M.P.H., Sc.D., of the Stanford University School of Medicine, Palo Alto, Calif., (and also Contributing Editor, JAMA), comment on the findings of this study in an accompanying editorial.

“The findings of Yunos and colleagues are important and should serve to focus more attention on the formulation of intravenous fluids. In light of the central role for intravenous fluids in perioperative, intensive, and nonintensive hospital care and the effects of fluid administration on physiology, biochemistry, clinical outcomes, and adverse events, intravenous fluid preparations are like drugs and deserve similar scientific and regulatory scrutiny. When physicians order an infusion of normal saline, Hartmann solution, or 20 percent albumin, these fluids bypass the gut, sometimes overrule the kidney, and reach into the deepest intracellular and interstitial crevices of the body. Clinicians owe it to patients to get intravenous fluid administration right.”

Editor’s Note: Please see the article for additional information, including financial disclosures, funding and support, etc.

To contact corresponding author Rinaldo Bellomo, M.D., F.C.I.C.M., email .(JavaScript must be enabled to view this email address). To contact editorial co-author Sushrut S. Waikar, M.D., M.P.H., call Jessica Maki at 617-534-1603 or email .(JavaScript must be enabled to view this email address).

###

Rinaldo Bellomo
.(JavaScript must be enabled to view this email address)
JAMA and Archives Journals